RAIN

Rain Enhancement Technologies Holdco, Inc.
CAPPED RATING

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.

Rain Enhancement Technologies Holdco, Inc. (RAIN) is rated D+ (1.6/5) on Deltasharpe Prism, scored against Industrials sector peers. Its strongest pillar is Growth (C+); its weakest is Value (F).

Quantitative Factor Evaluation • Updated

Overall Rating
1.6 / 5.0
D+
Value
F
Factor Score 0.0 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
D+
Factor Score 1.7 / 5.0
Momentum
D+
Factor Score 1.6 / 5.0
Revisions
C
Factor Score 2.3 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA -1.7
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -14.9%
Price Return 12M -85.7%
Catalyst Signal 0.00
Market Cap $8.8M
TTM Revenue $10.5K
Price / Sales 835.9
ROE N/A

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 F (0.0) C+ (2.5) D+ (1.7) D+ (1.6) C (2.3) D+ (1.6)
2026-11-07 F (0.0) C+ (2.5) D+ (1.7) D- (0.8) C (2.3) D (1.4)
2026-10-31 F (0.0) C+ (2.5) D+ (1.7) F (0.4) C (2.2) D (1.4)
2026-10-24 F (0.0) C+ (2.5) D+ (1.7) F (0.5) C (2.2) D (1.4)
2026-10-17 F (0.0) C+ (2.5) D+ (1.7) F (0.3) C (2.2) D (1.3)
Page 1 of 3